Ortivus AB (publ) (STO:ORTI.B)
Sweden · Delayed Price · Currency is SEK 1.420
-0.020 (-1.39%)
At close: Mar 27, 2026
Ortivus AB Revenue
In the year 2025, Ortivus AB had annual revenue of 73.40M SEK, down -8.72%. Ortivus AB had revenue of 18.75M in the quarter ending December 31, 2025, a decrease of -11.81%.
Revenue
73.40M
Revenue Growth
-8.72%
P/S Ratio
1.72
Revenue / Employee
1.93M
Employees
38
Market Cap
126.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.40M | -7.01M | -8.72% |
| Dec 31, 2024 | 80.41M | -3.67M | -4.36% |
| Dec 31, 2023 | 84.08M | -20.43M | -19.55% |
| Dec 31, 2022 | 104.51M | 10.24M | 10.86% |
| Dec 31, 2021 | 94.27M | -13.31M | -12.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.97B |
| Swedish Orphan Biovitrum AB | 28.24B |
| Medicover AB | 25.74B |
| Sectra AB | 3.52B |
| Xbrane Biopharma AB | 152.35M |
| Physitrack | 146.31M |
| Arcoma AB | 130.80M |
| IRLAB Therapeutics AB | 57.46M |